Brian Abrahams is ranked #1620 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Brian Abrahams (RBC Capital) — Analyst Ratings, Accuracy & Track Record

Q: How accurate are Brian Abrahams's stock ratings?

About 54% of Brian's ratings were profitable over a one-year hold, with an average return of +6.6% per rating, measured by 13Foresight from historical prices.

Analyst Tracker/Brian Abrahams

RBC

Brian Abrahams

RBC Capital

Wall Street Analyst

★★★☆☆

#1620

on 13Foresight · ranked by our own returns

54%

Success Rate

+6.6%

Average Return

43 of 80 calls profitable · -12548.9% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compare To ⓘ

📈 Across the calls we could measure, roughly 54% of Brian Abrahams's ratings turned a profit when each position was held for 1 year — averaging +6.6% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

144 Buy 114 Hold 4 Sell

Brian's Stock Coverage 64 ratings · 2026-07-12

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return
ACAD ACADIA Pharmaceuticals	Jul 07, 2026	BUY	Strong Buy +37.4% avg upside 42 analysts	$36.00 37.21% Upside	-0.4%
KPTI Karyopharm Therapeutics	Jul 07, 2026	BUY	Strong Buy +115.8% avg upside 18 analysts	$16.00 54.66% Upside	+2.9%
PTCT PTC Therapeutics	Jul 07, 2026	HOLD	Strong Buy -8.1% avg upside 29 analysts	$85.00 0.26% Upside	+1.2%
SRPT Sarepta Therapeutics	Jul 07, 2026	HOLD	Buy +215.0% avg upside 49 analysts	$19.00 0.34% Upside	-4.2%
VRTX Vertex Pharmaceuticals	Jul 07, 2026	BUY	Strong Buy -9.5% avg upside 61 analysts	$570.00 17.34% Upside	-7.1%
REGN Regeneron	Jul 07, 2026	HOLD	Strong Buy +16.2% avg upside 58 analysts	$696.00 4.73% Upside	-1.7%
NBIX Neurocrine	Jul 07, 2026	BUY	Strong Buy -1.8% avg upside 37 analysts	$195.00 10.00% Upside	-0.2%
INCY Incyte	Jul 07, 2026	HOLD	Buy -14.2% avg upside 47 analysts	$99.00 15.14% Downside	-1.1%
GILD Gilead Sciences	Jul 07, 2026	HOLD	Strong Buy -8.3% avg upside 66 analysts	$120.00 7.51% Downside	-4.8%
BIIB Biogen	Jul 07, 2026	BUY	Strong Buy +24.2% avg upside 52 analysts	$242.00 21.61% Upside	-3.2%
BCRX BioCryst	Jul 07, 2026	BUY	Strong Buy +77.0% avg upside 24 analysts	$14.00 34.00% Upside	·
DMRA Damora Therapeutics	Jun 30, 2026	BUY	Strong Buy -4.4% avg upside 19 analysts	$40.00 40.30% Upside	·
EVMN Evommune, Inc.	Jun 29, 2026	BUY	Strong Buy +217.1% avg upside 12 analysts	$30.00 127.16% Upside	-12.2%
APGE Apogee Therapeutics	Jun 23, 2026	HOLD	Buy -7.3% avg upside 19 analysts	$135.00 0.99% Upside	+0.5%
DFTX Definium Therapeutics	Jun 22, 2026	BUY	Strong Buy -8.4% avg upside 20 analysts	$57.00 21.13% Upside	+32.1%
CRBP Corbus Pharmaceuticals	May 26, 2026	BUY	Strong Buy +266.6% avg upside 20 analysts	$36.00 271.86% Upside	·
ATYR aTyr Pharma	May 15, 2026	HOLD	Buy +1440.5% avg upside 17 analysts	$1.00 83.63% Upside	·
GHRS GH Research	May 14, 2026	BUY	Strong Buy +37.9% avg upside 11 analysts	$40.00 50.83% Upside	+19.4%
LKFT Lakefront Biotherapeutics	May 13, 2026	HOLD	Buy +249.3% avg upside 24 analysts	$28.00 7.47% Downside	·
SION Sionna Therapeutics, Inc.	May 12, 2026	SELL	Strong Buy +19.0% avg upside 11 analysts	$23.00 49.17% Downside	-7.5%
PLRX Pliant Therapeutics	May 11, 2026	HOLD	Buy +1889.7% avg upside 21 analysts	$2.00 78.62% Upside	-5.8%
MLTX MoonLake Immunotherapeutics	May 11, 2026	HOLD	Strong Buy +43.0% avg upside 20 analysts	$16.00 21.48% Downside	+8.1%
PRTA Prothena	May 08, 2026	HOLD	Buy +152.2% avg upside 14 analysts	$13.00 40.78% Upside	-13.9%
XENE Xenon	May 07, 2026	BUY	Strong Buy -8.6% avg upside 28 analysts	$82.00 19.04% Upside	+13.2%
AARD Aardvark Therapeutics, Inc.	May 07, 2026	HOLD	Buy +151.4% avg upside 12 analysts	$6.00 21.05% Downside	-2.9%
NMRA Neumora Therapeutics, Inc.	May 07, 2026	BUY	Buy +369.6% avg upside 11 analysts	$7.00 316.60% Upside	-18.0%
CTNM Contineum Therapeutics, Inc. Class A	May 05, 2026	BUY	Strong Buy +34.1% avg upside 8 analysts	$22.00 44.83% Upside	+5.6%
KYMR Kymera Therapeutics	Apr 30, 2026	BUY	Strong Buy -15.1% avg upside 36 analysts	$106.00 11.10% Downside	+47.2%
NRIX Nurix Therapeutics	Apr 08, 2026	BUY	Strong Buy +35.3% avg upside 28 analysts	$30.00 30.18% Upside	+59.2%
TSE:SOBO South Bow Corp	Oct 26, 2025	BUY	Hold -10.4% avg upside 20 analysts	$39.00 23.61% Downside	·
ENTA Enanta Pharmaceuticals	Oct 02, 2023	HOLD	Buy +139.5% avg upside 17 analysts	$15.00 9.49% Upside	+7.2%
VERX Vertex	Oct 28, 2022	HOLD	Buy +181.8% avg upside 23 analysts	$288.00 2226.42% Upside	+27.8%
ATAI Atai Beckley N.V.	May 16, 2022	HOLD	Strong Buy +161.5% avg upside 16 analysts	$8.00 54.64% Upside	-52.0%
OVID Ovid Therapeutics	Aug 16, 2021	HOLD	Strong Buy +88.4% avg upside 17 analysts	$4.00 58.66% Upside	-41.2%
AMGN Amgen	Oct 26, 2017	HOLD	Buy -17.8% avg upside 57 analysts	$188.00 48.18% Downside	+8.4%
ABEO Abeona Therapeutics	Sep 15, 2017	BUY	Strong Buy +144.5% avg upside 17 analysts	$23.00 229.50% Upside	-16.6%
CVX Chevron	May 17, 2017	BUY	Strong Buy +5.0% avg upside 43 analysts	$135.00 23.50% Downside	+28.4%
RARE Ultragenyx Pharmaceutical	May 08, 2017	HOLD	Strong Buy +96.9% avg upside 36 analysts	$68.00 101.05% Upside	-3.8%
OSK Oshkosh	Apr 27, 2017	BUY	Strong Buy -1.7% avg upside 26 analysts	$80.00 45.25% Downside	+3.1%
FE FirstEnergy	Mar 31, 2017	HOLD	Buy +1.4% avg upside 25 analysts	$32.00 33.28% Downside	+12.0%
ARCT Arcturus Therapeutics	Mar 31, 2017	HOLD	Buy +321.0% avg upside 36 analysts	$8.75 25.47% Upside	-31.1%
PEG Public Service Enterprise	Mar 31, 2017	HOLD	Buy +5.9% avg upside 32 analysts	$46.50 42.22% Downside	+17.5%
QURE uniQure	Mar 07, 2017	HOLD	Strong Buy +38.5% avg upside 29 analysts	$8.00 81.22% Downside	+345.4%
AFMDQ Affimed	Feb 16, 2017	HOLD	Buy +12648900.0% avg upside 15 analysts	$2.50 2499900.09% Upside	·
DBVT DBV Technologies SA - American	Feb 09, 2017	BUY	Strong Buy +46.3% avg upside 15 analysts	$47.00 185.05% Upside	-36.6%
HAE Haemonetics	Jan 05, 2017	BUY	Buy -10.7% avg upside 17 analysts	$42.00 44.90% Downside	+59.1%
CLDX Celldex	Nov 23, 2016	HOLD	Strong Buy -0.0% avg upside 28 analysts	$5.00 87.31% Downside	-34.0%
RRC Range Resources	Nov 16, 2016	BUY	Buy +7.0% avg upside 43 analysts	$46.00 29.62% Upside	-49.8%
CMCSA Comcast	Nov 16, 2016	BUY	Buy +67.8% avg upside 41 analysts	$38.50 63.29% Upside	+11.7%
CVS CVS Health	Nov 01, 2016	BUY	Strong Buy -1.6% avg upside 39 analysts	$122.00 17.11% Upside	-15.2%
BMRN BioMarin Pharmaceutical	Sep 07, 2016	BUY	Strong Buy +59.6% avg upside 52 analysts	$120.00 102.88% Upside	-5.9%
TEVA Teva Pharmaceutical	Aug 25, 2016	BUY	Buy -10.8% avg upside 39 analysts	—	-67.2%
ABBV AbbVie	Aug 25, 2016	BUY	Strong Buy -6.7% avg upside 46 analysts	—	+16.3%
BMY Bristol-Myers Squibb	Aug 22, 2016	HOLD	Buy +2.3% avg upside 42 analysts	—	+0.1%
AGEN Agenus	Aug 08, 2016	BUY	Strong Buy +137.1% avg upside 17 analysts	—	-37.3%
LLY Eli Lilly & Co	Aug 08, 2016	BUY	Strong Buy -13.6% avg upside 47 analysts	—	+3.1%
JNJ Johnson & Johnson	Aug 01, 2016	HOLD	Strong Buy -14.0% avg upside 36 analysts	—	+8.5%
PFE Pfizer	Jul 15, 2016	BUY	Buy +39.2% avg upside 45 analysts	—	-5.6%
CLLS Cellectis SA	Jul 15, 2016	BUY	Strong Buy +571.3% avg upside 16 analysts	—	+8.1%
MRK Merck & Company	Jul 15, 2016	HOLD	Strong Buy +4.0% avg upside 43 analysts	—	+8.9%
NVS Novartis	Apr 21, 2016	BUY	Hold -11.8% avg upside 24 analysts	$60.50 60.66% Downside	-0.3%
RIGL Rigel	Feb 23, 2015	HOLD	Buy -43.9% avg upside 17 analysts	—	-28.2%
PLX Protalix	Jun 25, 2012	HOLD	Buy +241.5% avg upside 4 analysts	—	-16.3%
NVAX Novavax	Sep 02, 2009	HOLD	Hold +148.7% avg upside 20 analysts	—	-60.9%

🔒 59 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Brian Abrahams — Frequently Asked Questions

How accurate are Brian Abrahams's stock ratings?

Based on the calls 13Foresight could measure, about 54% of Brian's ratings were profitable over a one-year hold, with an average return of +6.6% per rating, or -1.4% versus the S&P 500. We score every analyst the same way, from historical prices.

How is Brian ranked on 13Foresight?

Brian Abrahams is currently ranked #1620 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Brian cover?

Brian most recently has ratings on ACAD, KPTI, PTCT, SRPT, VRTX, REGN, NBIX, INCY, GILD, BIIB, BCRX, DMRA and 52 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Rating Distribution

Welcome to 13Foresight!